About this trial
This study compares synthetic mammography to full-field digital mammography in image interpretation and performance metrics. Digital breast tomosynthesis (DBT) has previously been found to be superior in performance to standard digital mammography in both screening and diagnostic settings for the early detection and improved diagnosis of breast cancers. DBT in combination with full-field digital mammography (FFDM) reduces recall rates and increases cancer detection rates relative to FFDM alone. Synthetic mammography is a 2-dimensional reconstructed image, using the dataset derived from the DBT acquisition, without requiring additional radiation dose. Collecting information from patients' medical records may help doctors analyze the characteristics, utility, and impact of synthetic mammography to compared to FFDM.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female
Age 18 or older
Consecutive cases in breast imaging center
Disqualifiers
Cases demonstrate administrative or technical errors (e.g. missing views, labeling inconsistent with report, etc.)
Trial population
Patients who have undergo mammography between August 1, 2018 and August 31, 2020
Trial design
Case-control
Retrospective
Treatments tested in this trial
Electronic Health Record Review
Other interventionReview of medical records and past imaging examinations
Treatment groups
Trial outcomes
Primary outcomes
To analyze the impact of synthetic mammography (SM), as compared with full-field digital mammography (FFDM
Sponsors and contacts
Click on the lead sponsor to view all of their trials.